BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 30529681)

  • 1. Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.
    Filì C; Candoni A; Zannier ME; Olivieri J; Imbergamo S; Caizzi M; Nadali G; Di Bona E; Ermacora A; Gottardi M; Facchinelli D; Ciancia R; Lazzarotto D; Dubbini MV; Festini G; Gherlinzoni F; Michieli MG; Semenzato G; Fanin R
    Leuk Res; 2019 Jan; 76():33-38. PubMed ID: 30529681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy.
    Bocchia M; Candoni A; Borlenghi E; Defina M; Filì C; Cattaneo C; Sammartano V; Fanin R; Sciumè M; Sicuranza A; Imbergamo S; Riva M; Fracchiolla N; Latagliata R; Caizzi E; Mazziotta F; Alunni G; Di Bona E; Crugnola M; Rossi M; Consoli U; Fontanelli G; Greco G; Nadali G; Rotondo F; Todisco E; Bigazzi C; Capochiani E; Molteni A; Bernardi M; Fumagalli M; Rondoni M; Scappini B; Ermacora A; Simonetti F; Gottardi M; Lambertenghi Deliliers D; Michieli M; Basilico C; Galeone C; Pelucchi C; Rossi G
    Hematol Oncol; 2019 Oct; 37(4):447-455. PubMed ID: 31385337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.
    Stahl M; DeVeaux M; Montesinos P; Itzykson R; Ritchie EK; Sekeres MA; Barnard JD; Podoltsev NA; Brunner AM; Komrokji RS; Bhatt VR; Al-Kali A; Cluzeau T; Santini V; Fathi AT; Roboz GJ; Fenaux P; Litzow MR; Perreault S; Kim TK; Prebet T; Vey N; Verma V; Germing U; Bergua JM; Serrano J; Gore SD; Zeidan AM
    Blood Adv; 2018 Apr; 2(8):923-932. PubMed ID: 29685952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
    Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
    Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical Efficacy of Decitabine-Based Chemotherapy Regimens in the Treatment of Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia].
    Li GH; Chen RA; Ji YR; Qin WW; Chen Y; Wang WQ; Liu C; Zhou NC; Liu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):743-749. PubMed ID: 29950214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Choi EJ; Lee JH; Park HS; Lee JH; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):290-299.e3. PubMed ID: 30879987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
    Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
    Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study.
    Li X; Dong Y; Li Y; Ren R; Wu W; Zhu H; Zhang Y; Hu J; Li J
    BMC Cancer; 2019 Aug; 19(1):819. PubMed ID: 31429724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia.
    Park H; Chung H; Lee J; Jang J; Kim Y; Kim SJ; Kim JS; Min YH; Cheong JW
    Yonsei Med J; 2017 Jan; 58(1):35-42. PubMed ID: 27873493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.
    Bhatnagar B; Duong VH; Gourdin TS; Tidwell ML; Chen C; Ning Y; Emadi A; Sausville EA; Baer MR
    Leuk Lymphoma; 2014 Jul; 55(7):1533-7. PubMed ID: 24144313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
    Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
    Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 16. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
    Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
    Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia.
    Feng X; Chen X; Nie S; Chang Y; Meng F; Zhou J; Mao C; Li T; Yan X; Huang J; Liu S; Gao Y; Xiao S
    J Cancer Res Ther; 2019; 15(7):1471-1476. PubMed ID: 31939424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
    Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M
    Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy.
    Lübbert M; Rüter BH; Claus R; Schmoor C; Schmid M; Germing U; Kuendgen A; Rethwisch V; Ganser A; Platzbecker U; Galm O; Brugger W; Heil G; Hackanson B; Deschler B; Döhner K; Hagemeijer A; Wijermans PW; Döhner H
    Haematologica; 2012 Mar; 97(3):393-401. PubMed ID: 22058219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.